279 related articles for article (PubMed ID: 23389469)
1. Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations.
Aigner J; Smetanay K; Hof H; Sinn HP; Sohn C; Schneeweiss A; Marmé F
Ann Surg Oncol; 2013 May; 20(5):1538-44. PubMed ID: 23389469
[TBL] [Abstract][Full Text] [Related]
2. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
3. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
4. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
5. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
6. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
8. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011.
Krishnan MS; Recht A; Bellon JR; Punglia RS
Breast Cancer Res Treat; 2013 Feb; 138(1):205-13. PubMed ID: 23338762
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of false-negative sentinel lymph nodes in breast cancer.
Zavagno G; Del Bianco P; Koussis H; Artioli G; Carraro P; De Salvo GL; Mencarelli R; Belardinelli V; Marconato G; Nitti D
Eur J Surg Oncol; 2008 Jun; 34(6):620-5. PubMed ID: 17764888
[TBL] [Abstract][Full Text] [Related]
10. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
[TBL] [Abstract][Full Text] [Related]
11. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond.
Gatzemeier W; Mann GB
Breast; 2013 Jun; 22(3):211-6. PubMed ID: 23478200
[TBL] [Abstract][Full Text] [Related]
12. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
13. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
14. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
[TBL] [Abstract][Full Text] [Related]
15. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
[TBL] [Abstract][Full Text] [Related]
16. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
[TBL] [Abstract][Full Text] [Related]
17. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
Shah-Khan M; Boughey JC
Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
[TBL] [Abstract][Full Text] [Related]
18. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
19. Axillary and systemic treatment of patients with breast cancer and micrometastatic disease or isolated tumor cells in the sentinel lymph node.
Maaskant-Braat AJ; Voogd AC; van de Poll-Franse LV; Coebergh JW; Nieuwenhuijzen GA
Breast; 2012 Aug; 21(4):524-8. PubMed ID: 22516371
[TBL] [Abstract][Full Text] [Related]
20. Potential Impact of the Z0011 Trial on the Omission of Axillary Dissection: A Retrospective Cohort Study.
Shinzato JY; Serra KP; Eugeni C; Cabello C; Cardoso-Filho C; Zeferino LC
Rev Bras Ginecol Obstet; 2021 Apr; 43(4):297-303. PubMed ID: 33784760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
